Table 1.
oHSVs in clinical trials for Glioma.
| oHSV Name | Genetic Alterations | Transgene | oHSV Ref | Disease | Current Developer | Clinical Trial Phase | Clinical Trial ID | Pre- or Clinical Ref |
|---|---|---|---|---|---|---|---|---|
| HSV1716 (Sephrevir®) | γ34.5Δ | (MacLean et al., 1991) | Recurrent HGG | Sorrento Therapeutics | 1 | NCT02031965 | (Rampling et al., 2000; Papanastassiou et al., 2002; Harrow et al., 2004) | |
| G207 | γ34.5Δ, ICP6- | lacZ in ICP6 | (Mineta et al., 1995) | Recurrent GBM Recurrent Ped HGG Ped Supratentorial Recurrent HGG Ped Cerebellar |
Treovir, Inc | 1/2 | NCT00028158 NCT04482933 NCT02457845 NCT00157703 NCT03911388 | (Markert et al., 2000; Markert et al., 2009; Markert et al., 2014; Friedman et al., 2021; Miller et al., 2022) |
| G47Δ (DELYTACT®; Teserpaturev) | γ34.5Δ, ICP6-, and ICP47Δ | LacZ in ICP6 | (Todo et al., 2001) | Recurrent/Progressive GBM | Daiichi Sankyo, Inc. | 1/2 | UMIN000002661 | (Todo et al., 2022a; Todo et al., 2022b) |
| C134 (MB-108) |
γ34.5Δ | HCMV IRS1 driven by HCMV IEpro inserted in UL3-UL4 intragenic region | (Shah et al., 2007) | Recurrent malignant glioma | Mustang Bio | 1 | NCT03657576 | (Cassady et al., 2017) |
| rQNestin34.5v.2 (CAN-3110) |
γ34.5Δ, ICP6- | γ34.5 driven by the nestin enhancer-hsp68pro in ICP6 | (Kambara et al., 2005) | Recurrent malignant glioma | Candel Therapeutics | 1 | NCT03152318 | (Chiocca et al., 2020) |
| M032 (NSC-733972) |
γ34.5Δ | IL-12 driven by murine early-growth response-1 pro (Egr-1) in γ34.5 | (Roth et al., 2014) | Recurrent or new GBM | University of Alabama at Birmingham | 1/2 | NCT02062827 NCT05084430 | (Patel et al., 2016) |
Ped, pediatric; Pro, Promoter; Ref, References.